Varicella

Trump's 'vaccine hesitant’ views run against public opinion, Pew says

As many experts wait anxiously to see how President Donald Trump might act on vaccines, a new survey documents strong support by Americans that the benefits of childhood immunizations outweigh any potential risks.
 
Pew Research Center reports that 88% of Americans think the benefits of the MMR vaccine outweigh the risks, while one in 10 believe the risks aren’t worth the benefits.
 
The survey—conducted from May 10 to June 6 last year—found that 82% of Americans are in favor of MMR vaccination requirements for healthy schoolchildren.
Undefined

Beyond Ebola, keeping patients and health workers safe

Dr Doussou Touré arrives for work at Coléah Medical Centre. She washes her hands from a bucket set up in front of the building, proceeds to a screening area where her temperature is checked and recorded and only then enters the bustling facility that she supervises.
 
“Ebola is under control now, but we try to keep up the infection prevention and control systems that were put in place during the outbreak,” Dr Touré says, pointing to several sturdy, brightly-coloured bins, each one designated for the disposal of varying waste matter.
 
Undefined

China needs tougher enforcement of vaccine regulation: WHO

China must strengthen regulation of its market for vaccines, the World Health Organization (WHO) said on Monday, after a bust of an illegal black market drugs ring this month underscored the country's regulatory weaknesses.
 
Police have arrested more than 130 suspects over a scandal in which 310 million yuan ($48 million) of illegal vaccines was sold onto the market. The value of the illegal trades could be as much as $90 million.
 
Undefined

Afrique: Vaccination infantile - L'Afrique, le continent le moins protégé

La première conférence ministérielle africaine sur la vaccination a ouvert ses travaux, le mercredi 24 février 2016 à Addis Abeba en Ethiopie. Des ministres de la Santé, des Finances, des experts, des décideurs, des bailleurs de fonds et de la société civile réfléchissent aux moyens les plus efficaces afin de parvenir à une couverture vaccinale de tous les enfants du continent.
 
Etendre la vaccination afin de parvenir à une couverture universelle est le nouveau challenge que les dirigeants africains et leurs partenaires veulent se donner en matière de santé.
Undefined

Canada: 1,5 % des enfants n'ont jamais reçu de vaccins

Même s'il a été démontré scientifiquement que la vaccination infantile permet d'éviter plusieurs maladies potentiellement mortelles, 1,5 % des enfants canadiens âgés de deux ans n'ont jamais reçu de vaccins de quelque type que ce soit.
 
C'est ce que révèlent les résultats de l'«Enquête sur la couverture vaccinale des enfants (ECVNE)» de l'année 2013, publiés mardi par Statistique Canada. L'étude a été menée auprès des parents ou tuteurs de plus de 40 000 enfants âgés de 2 à 17 ans.
 
Undefined

Engineering A Shingles Vaccine That Doesn't Wimp Out Over Time

If you had chickenpox as a child, then you're at risk for shingles. As you age, the risk increases, probably because the immune system weakens over time.
 
The varicella zoster virus can hide in the body over a lifetime and suddenly activate, causing a painful, blistery rash. Even when the rash disappears, pain can linger and worsen, causing a burning, shooting, stabbing pain so severe it can leave people unable to sleep, work or carry on other activities.
 
Undefined

Solid, heat-resistant vaccine to ease immunisation processes

EU researchers have set out to substitute liquid and freeze-dried vaccines for new, solid state candidates. If successful, the research will enable the large scale production of new virosome-based vaccines with increased stability, longer shelf life and less invasive administration methods.
 
To this day, immunisation remains the most effective way to eradicate diseases. Their widespread use has helped reduce the incidence of diseases such as hepatitis A, polio, rubella, tetanus or varicella by over 90 % compared to pre-vaccine era.
Undefined

GlaxoSmithKline's shingles vaccine gets a leg up on Merck's rival with a PhIII win

GlaxoSmithKline's ($GSK) in-development shingles vaccine successfully staved off the virus in a massive Phase III study--and, in contrast with its top competitor, the shot's effects didn't wane among elderly patients.
 
The vaccine, HZ/su, reduced the risk of shingles by 97.2% compared with placebo in a study involving more than 16,000 patients, GSK said, maintaining its efficacy across all age groups. That latter point is particularly important, as Merck's ($MRK) Zostavax, the only approved shingles vaccine, tends to lose steam as patients approach 70.
Undefined

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to suspected deaths stemming from vaccination and some companies' (such as Shenzhen Kangtai, Tiantan Biological and Dalian Hissen) production halts of some products because of their failure to pass new GMP certification, China's human vaccine lot release volume in 2014 declined by 2.4% year on year to 791 million doses.
 
Undefined

Pages